EMG
MRNS

ETF Managers Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

ETF Managers Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-101,921
Closed -$1.16M – 762
2021
Q3 		$1.16M Buy
+101,921
New +$1.4M 0.02% 253

Other funds holding MRNS

LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

ETF Managers Group's MRNS Position: Q4 2021 in Review

ETF Managers Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2021, closing a stake of 101,921 shares — an estimated $1.16M sold.

ETF Managers Group first reported a position in MRNS in Q3 2021 and held it in 1 quarter. The position peaked at $1.16M in Q3 2021. 75 funds tracked by Wall St. Rank hold MRNS as of Q4 2021.

  • ETF Managers Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
  • ETF Managers Group sold 101,921 Marinus Pharmaceuticals, Inc shares in Q4 2021, an estimated $1.16M.
  • ETF Managers Group first reported a position in Marinus Pharmaceuticals, Inc in Q3 2021 and held it in 1 quarter.
  • ETF Managers Group's Marinus Pharmaceuticals, Inc position peaked at $1.16M in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2021.

Based on ETF Managers Group's 13F filing for Q4 2021, filed 14 Feb 2022.